Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

Antares starts dosing in Phase III QuickShot trial evaluating testosterone-deficient adult males By PBR Staff Writer
US-based Antares Pharma has dosed first patient in a Phase III trial designed to evaluate the efficacy and safety of QuickShot Testosterone (QS T) administered subcutaneously once each week to testosterone-deficient adult males.
Contract Research & Services > Clinical Trials > News
Dipexium enrols first patient in Phase III trials of Locilex By PBR Staff Writer
Dipexium Pharmaceuticals has enrolled first patient in the second of two pivotal Phase III clinical trials, called OneStep-1 and OneStep-2, evaluating its new, broad-spectrum, topical antibiotic peptide, Locilex (pexiganan cream 0.8%), to treat patients mild infections of diabetic foot ulcers, or Mild DFI.
Contract Research & Services > Clinical Trials > News Synergy closes patient enrollment in Phase II trial of SP-333 in patients OIC By PBR Staff Writer
US-based Synergy Pharmaceuticals has completed patient enrollment in its Phase II trial of SP-333, its next-generation uroguanylin analog, in patients with opioid-induced constipation (OIC).
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
Rexahn provides update on Phase I Supinoxin trial in cancer patients with solid tumors
Rexahn Pharmaceuticals, a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, has announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin (RX-5902) in cancer patients with solid tumors.
Contract Research & Services > Clinical Trials > News
Janssen to start phase III trial of daratumumab in multiple myeloma in Q4 2014
By PBR Staff Writer
Genmab partner Janssen Biotech (Janssen) is planning to start a new phase III trial of daratumumab for the treatment of patients with multiple myeloma during the fourth quarter of 2014.
Contract Research & Services > Clinical Trials > News
Pfizer releases positive results from Phase III trial of BeneFIX to treat hemophilia B
By PBR Staff Writer
US-based Pfizer has released positive results from its Phase III trial comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B.
Contract Research & Services > Clinical Trials > News
Alkermes begins Phase I trial of ALKS 8700 to treat multiple sclerosis
By PBR Staff Writer
Ireland-based biopharmaceutical firm Alkermes has started a Phase I clinical trial of ALKS 8700, a novel monomethyl fumarate (MMF) molecule being developed for the treatment of multiple sclerosis (MS).
Contract Research & Services > Clinical Trials > News
Auspex begins pivotal Phase 2/3 clinical trial for SD-809 in Tardive Dyskinesia
Auspex Pharmaceuticals, a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, has announced the enrollment of the first two patients in a multi-center pivotal Phase 2/3 clinical trial of its investigational drug, SD-809 (deutetrabenazine), for the treatment of tardive dyskinesia (TD).
Contract Research & Services > Clinical Trials > News
BMS, Pfizer begin patient enrollment in Phase IV EMANATE trial of Eliquis
By PBR Staff Writer
Bristol-Myers Squibb (BMS) and Pfizer have started patient enrollment in a Phase IV clinical trial called EMANATE (Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnTicoagulation in subjEcts with NVAF) evaluating the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion.
Contract Research & Services > Clinical Trials > News
OncoMed initiates Phase 2 ALPINE clinical trial of Tarextumab
OncoMed Pharmaceuticals, a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in the randomized, placebo-controlled Phase 2 portion of the company's "ALPINE" (Antibody therapy in first-Line Pancreatic cancer Investigating anti-Notch Efficacy and safety) clinical trial of its anti-Notch 2/3 cancer stem cell antibody, tarextumab (OMP-59R5), being studied for the treatment of pancreatic cancer.
Contract Research & Services > Clinical Trials > News
ImQuest to initiate clinical trials of a Vaginal Gel for the prevention of HIV transmission to women
ImQuest Pharmaceuticals was recently notified by the US Food and Drug Administration of the approval of its Investigational New Drug (IND) application to study the safety in Phase 1 clinical trials of its vaginal gel containing the nonnucleoside reverse transcriptase HIV Inhibitor IQP-0528.
Contract Research & Services > Clinical Trials > News
ZS Pharma completes patient enrollment in phase III trial of hyperkalemia treatment
By PBR Staff Writer
ZS Pharma, a US-based biopharmaceutical firm, has completed patient enrollment in its second phase III clinical trial (ZS004) of ZS-9 (sodium zirconium cyclosilicate) for the treatment of hyperkalemia.
Contract Research & Services > Clinical Trials > News
Targacept Phase IIb trial in Alzheimer’s disease fails to show superiority of TC-1734 over Donepezil
Targacept, a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, has announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer’s disease.
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250